Index

Note: Page numbers with prefix '*f*' refers to figures and '*t*' refers to tables.

A

abdominal organs
  MRI applications in, 215, 215*f*, 216*f*
acquisition matrix, 91
acquisition parameter modification
  in motion artifact reduction, 126–7, 127*f*, 128*f*
actively shielded gradient coil, 184
ADC. *See* analog-to-digital converter (ADC)
advanced imaging applications, 147–61. *See also specific types, e.g.,* perfusion
  diffusion, 147–53, 148*f*, 150*f*, 152*f*
  diffusion-weighted imaging–related, 151–3
  fMRI, 156–7
  noble gas imaging, 159–61, 160*f*
  perfusion, 153–5, 154*f*–6*f*
  ultra-high field imaging, 158–9
AET. *See* Applications Entity Title (AET)
agitated patients
  MRI in, 221
aliasing, 105, 107–8, 107*f*–10*f*
amplitude
  in RV waveform characterization, 40
analog-to-digital converter (ADC), 12–13
Applications Entity Title (AET), 180
arterial spin labeling (ASL)
  continuous, 153
  in perfusion studies, 153
  pulsed, 153
artifact(s), 103–25. *See also specific types, e.g.,* motion artifacts
  "blooming," 120
  chemical shift, 108–111, 109*f*, 111*f*, 111*t*
  coherence, 113, 115–17, 115*f*–18*f*
  described, 103
  external, 119–25
  flow misregistration, 104, 105*f*, 106*f*
  magnetic susceptibility difference, 117, 118*f*, 120–1, 121*f*
  motion, 103–5, 105*f*, 106*f*
  phase cancellation, 110–11, 111*f*, 111*t*
  radial, 119, 120*f*
  sequence protocol–related, 105, 107–19
  truncation, 112, 112*f*–14*f*
ASL. *See* arterial spin labeling (ASL)
atom
  structure of, 2

B

b value
  in diffusion, 148
base magnetic field
  safety precautions related to, 197
benzoxypropionic tetraacetate (BOPTA)
  in MRI, 191
black-blood MRA techniques, 135
BLADE, 134, 134*f*
"blooming" artifact, 120
BOLD fMRI studies, 157
Boltzmann distribution, 7
BOPTA. *See* benzoxypropionic tetraacetate (BOPTA)
bowel
  MRI applications in, 215, 215*f*
brain
  MRI applications in, 203, 203*f*, 204*f*
breast
  MRI applications in, 209–10
bright-blood MRA images, 145, 146*f*
Brownian motion, 147
bulk magnetic susceptibility, 8–9

C

Carr–Purcell–Meiboom–Gill (CPMG) technique, 184
CASL. *See* continuous arterial spin labeling (CASL)
center frequency
  in RV waveform characterization, 40
cerebral ischemia
  diffusion-weighted imaging in evaluation of, 151–3
chemical shift
  in MR, 14–16, 15*f*, 16*f*
  in MRS, 162–4, 163*f*, 164*f*
chemical shift artifacts, 108–10, 109*f*
  of second kind, 110–11, 111*f*, 111*t*
chemical shift imaging (CSI), 169
chronic kidney disease (CKD)
  classification of, 193, 193*t*
CKD. *See* chronic kidney disease (CKD)
clinical applications, 200–21
  abdominal organs, 215, 215*f*, 216*f*

MRI Basic Principles and Applications, Fifth Edition.
Brian M. Dale, Mark A. Brown and Richard C. Semelka.

© 2015 John Wiley & Sons, Ltd. Published 2015 by John Wiley & Sons, Ltd.

clinical applications (*continued*)
brain, 203, 203*f*, 204*f*
breast, 209–10
common bile duct, 215, 216*f*
for ETSE, 220
examination design considerations in, 202
general principles of, 200–2
great vessels, 210–11, 211*f*, 212*f*
heart, 210–11, 211*f*, 212*f*
kidneys, 215, 216*f*
knee, 207*f*, 208*f*
liver, 211–15, 213*f*, 214*f*
musculoskeletal, 206, 207*f*–9*f*
neck, 204–5
for out-of-phase gradient echo, 219
pelvis, 215, 217, 217*f*, 218*f*
in sedated or agitated patients, 221
shoulder, 209*f*
for single-echo spin echo sequence, 218–19
specific sequences and clinical situations, 218–21
spine, 205–6, 205*f*, 206*f*
for spoiled gradient echo, 219
for standard multiecho spin echo, 220
for STIR imaging, 220
for *T1*-weighted techniques, 218–20
fat saturation, 219–20
for *T2*-weighted techniques, 220–1
fat saturation, 221
thorax, 206–9
coherence artifacts, 113, 115–17, 115*f*–18*f*
coil(s)
actively shielded gradient, 184
phased-array, 58–9, 60*f*, 61*f*
surface, 59, 60*f*
common bile duct
MRI applications in, 215, 216*f*
composite pulses, 44–5, 45*f*
computer systems
in MRI system, 177–80, 178*f*, 187
continuous arterial spin labeling (CASL), 153
continuous wave (CW) mode operation
in RF selective excitation, 39–44, 41*f*–3*f*
contrast agents, 189–95
advantages of, 189
adverse reactions to, 192–3, 193*t*
BOPTA in, 191
categorization of, 189
Feridex, 194–5
GBCAs, 190–3, 191*f*, 192*t*–3*t*
intravenous agents, 190–5, 191*f*, 192*t*–3*t*, 194*f*
negative agents, 195
oral agents, 195
safety precautions related to, 199
T1 relaxation agents, 190–3, 191*f*, 192*t*–3*t*
T2 relaxation agents, 194–5, 194*f*
contrast-to-noise ratio, 91
CPMG technique. *See* Carr–Purcell–Meiboom–Gill (CPMG) technique
crosstalk, 89–90, 90*f*
cryogen(s)
described, 197
safety precautions related to, 197–8
CSI. *See* chemical shift imaging (CSI)
CW. *See* continuous wave (CW)

D

data acquisition system
in MRI system, 178*f*, 186–8
data collection methods, 54–5, 54*f*–6*f*
demodulated signal, 13–14
DICOM (digital imaging and communications in medicine), 179–80
DICOM Service Class Uses and Service Class Provider, 180
diffusion, 147–53, 148*f*, 150*f*, 152*f*
defined, 147
described, 147–8, 148*f*
measurements of, 148–9
diffusion-weighted imaging
applications of, 151–3
digital imaging and communications in medicine (DICOM), 179–80
directional dependence
in diffusion measurement, 149–50, 152*f*
Dixon method
for fat suppression, 102, 102*f*
duration
in RV waveform characterization, 40

E

echo planar imaging (EPI) sequences, 75–7, 76*f*
MP pulses incorporated into, 82–5, 83*f*–5*f*
echo spacing, 88
echo time *(TE)*, 87–8, 88*f*
echo train inversion recovery sequence, 79*f*, 80
echo train length, 88
echo train spin echo (ETSE), 69–70, 69*f*
clinical applications for, 220
encoding
phase, 33–5, 33*f*, 34*f*
energy absorption
macroscopic, 10, 11*f*
microscopic, 10, 11*f*
EPI sequences. *See* echo planar imaging (EPI) sequences
ETSE. *See* echo train spin echo (ETSE)
excitation
RF
in MR, 10–12, 11*f*
RF selective, 39–44, 41*f*–3*f*
excitation angle, 88
excitation order
crosstalk and, 89–90, 90*f*
described, 90
external artifacts, 119–25
described, 119
magnetic field distortions, 120–2, 121*f*, 122*f*
magnetic susceptibility difference artifact, 120–1, 121*f*
measurement hardware, 122–4
noise, 123*f*–4*f*, 124–5

extrinsic parameters, 89–91, 90*f*
  effects of, 92*t*
  variables in, 93
extrinsic variables, 93

F
fat saturation techniques
  T1-weighted
    clinical applications for, 219–20
  T2-weighted
    clinical applications for, 221
FDA. *See* Food and Drug Administration (FDA)
Feridex
  in MRI, 194–5
ferumoxides, 194–5, 194*f*
FID. *See* free induction decay (FID)
field of view *(FOV)*, 91
FLAIR. *See* fluid-attenuated inversion recovery (FLAIR)
flip angle, 88
flow compensation
  in motion artifact reduction, 132–3, 133*f*
flow misregistration artifact, 104, 105*f*, 106*f*
fluid-attenuated inversion recovery (FLAIR), 81
fMRI. *See* functional MRI (fMRI)
Food and Drug Administration (FDA)
  on MRI safety, 196
4D time-resolved MR angiography with keyhole (4D-TRAK), 138
4D-TRAK (4D time-resolved MR angiography with keyhole), 138
Fourier imaging
  partial, 53, 53*f*
Fourier transformation, 103, 169, 171–3, 171*f*, 172*f*, 174*f*, 175*f*
FOV. See field of view *(FOV)*
free induction decay (FID), 12–13, 13*f*
frequency encoding, 30–2, 31*f*, 32*f*
frequency selective pulses
  in RV waveform characterization, 41–4, 42*f*, 43*f*
frequency selective saturation, 99–101, 99*f*, 100*f*
full-width at half-maximum height (FWHM), 165
functional brain imaging, 156–7
functional MRI (fMRI), 156–7
functional MRI (fMRI) studies
  BOLD, 157
FWHM. *See* full-width at half-maximum height (FWHM)

G
gadolinium-based contrast agents (GBCAs)
  in MRI, 190–3, 191*f*, 192*t*–3*t*
gating
  in motion artifact reduction, 127–32, 130*f*, 131*f*
Gaussian pulses
  in RV waveform characterization, 42, 43*f*
GBCAs. *See* gadolinium-based contrast agents (GBCAs)
Generalized Autocalibrating Partially Parallel Acquisition (GRAPPA), 63–4, 64*f*
GMR. *See* gradient motion rephasing (GMR)
gradient(s), 182
  safety precautions related to, 198
gradient coil
  actively shielded, 184
gradient echo sequences, 70–5, 71*t*, 72*f*–5*f*. *See also specific types*
  absence of 180* RF pulse in, 70–1, 71*t*
  acronyms for, 71*t*
  described, 70
  MP pulses incorporated into, 82–5, 83*f*–5*f*
  refocused, 71*t*, 72–5, 72*f*–5*f*. *See also* refocused gradient echo sequences
  spoiled, 71–2, 71*t*
  steady-state, 71*t*, 72–5, 72*f*–5*f*
  types of, 71–5, 71*t*, 72*f*–5*f*
gradient fields, 26–8, 27*f*, 182
gradient motion rephasing (GMR), 132–3, 133*f*
gradient pulses, 183
gradient system
  in MRI system, 178*f*, 182–4, 188
GRAPPA (Generalized Autocalibrating Partially Parallel Acquisition), 63–4, 64*f*
great vessels
  MRI applications in, 210–11, 211*f*, 212*f*

H
hard pulses, 41, 41*f*
heart
  MRI applications in, 210–11, 211*f*, 212*f*
Hermitian symmetry, 53
hydrogen MRS, 162–76. *See also* magnetic resonance spectroscopy (MRS)
hyperbolic secant pulses
  in RV waveform characterization, 42, 43*f*

I
IEC. *See* International Electrotechnical Commission (IEC)
image-based parallel techniques, 62, 63*f*
image contrast
  measurement parameters and, 86–93
image data matrices
  raw data in, 46–7, 46*f*, 47*f*
image processing computer
  in MRI system, 178, 178*f*
instrumentation, 177–88. *See also specific components and* magnetic resonance imaging (MRI) system
International Electrotechnical Commission (IEC)
  on MRI safety, 196
intravenous agents
  in MRI, 190–5, 191*f*, 192*t*–3*t*, 194*f*
intravoxel incoherent motion, 148–9
intrinsic parameters, 87–9, 87*f*–9*f*
  effects of, 92*t*
  variables in, 92–3
intrinsic variables, 92–3
inversion recovery (IR) looping modes, 79*f*, 80
inversion recovery (IR) pulse sequences, 78–80, 78*f*, 78*t*
  acronyms for, 78*t*
  image reconstruction process in, 80, 81*f*, 82*f*
inversion time *(TI)*, 88–9, 89*f*
IR. *See* inversion recovery (IR)

J
J coupling
in MRS, 164–5, 166*f*

K
k-space
raw data and, 48–50, 49*f*, 51*f*
k-space filling techniques, 51–8
reduced, 51–3, 52*f*, 53*f*
reordered, 54–5, 54*f*–6*f*
types of, 56–8, 57*f*–9*f*
k-space formalism, 49–50, 51*f*
k-space trajectory, 54–5, 54*f*–6*f*
k-space-based techniques
GRAPPA, 63–4, 64*f*
parallel, 62, 63*f*
SMASH, 63–4
SNR in, 64
kidney(s)
MRI applications in, 215, 216*f*
knee
MRI applications in, 207*f*, 208*f*

L
Larmor equation, 6, 27
Larmor precession, 4–6, 5*f*
liver
MRI applications in, 211–15, 213*f*, 214*f*
localization techniques
in MRS, 167–9, 168*f*
loop(s)
sequence, 35–8, 36*f*, 37*f*

M
magnet(s)
in MRI system, 178*f*, 180–2, 187
magnet system
in MRI system, 178*f*, 180–2, 187
magnetic field(s), 1–2
magnetic field distortions, 120–2, 121*f*, 122*f*
magnetic field gradients, 26–7, 27*f*
magnetic resonance (MR)
chemical shift in, 14–16, 15*f*, 16*f*
concepts of, 10–16
described, 1
RF excitation in, 10–12, 11*f*
RF signal detection in, 12–14, 13*f*, 14*f*
magnetic resonance angiography (MRA), 135–46
approaches to, 135–46
described, 135–6
flow selection in, 135, 136*f*
MIP, 144–6, 145*f*, 146*f*
phase contrast, 141–4, 143*f*–4*f*
problems associated with, 136
techniques, 135–46
time-of-flight, 137–40, 137*f*–42*f*
magnetic resonance imaging (MRI)
advanced imaging applications for, 147–61. *See also specific types and* advanced imaging applications
in agitated patients, 221
artifacts in images, 103–25. *See also* artifact(s)
clinical applications of, 200–21. *See also* clinical applications
composite pulses in, 44–5, 45*f*
confusing aspects of, 65
contrast agents in, 189–95. *See also* contrast agents
data collection methods, 54–5, 54*f*–6*f*
functional, 156–7
gradient fields in, 26–8, 27*f*
initial step in, 28
k-space filling techniques in, 51–8. *See also* *k*-space filling techniques
nonrectilinear sampling in, 56
parallel acquisition methods in, 60–4, 63*f*, 64*f*
phase encoding in, 33–5, 33*f*, 34*f*
phased-array coils in, 58–9, 60*f*, 61*f*
principles of, 26–64
projection reconstruction in, 57, 58*f*
pulse sequences in, 65–85. *See also* pulse sequence(s)
radial scanning in, 57, 58*f*
ramped sampling in, 56–7, 57*f*
raw data in
image data matrices and, 46–7, 46*f*, 47*f*
k-space and, 48–50, 49*f*, 51*f*
readout or frequency encoding in, 30–2, 31*f*, 32*f*
reduced *k*-space techniques in, 51–3, 52*f*, 53*f*
reordered *k*-space filling techniques in, 54–5, 54*f*–6*f*
RF selective excitation in, 39–44, 41*f*–3*f*
safety precautions in, 196–9. *See also* safety precautions
in sedated patients, 221
sequence looping in, 35–8, 36*f*, 37*f*
slice selection in, 28–9, 28*f*–30*f*
SNR and tradeoffs in, 47–8
two-dimensional spiral sampling in, 58, 59*f*
magnetic resonance imaging (MRI) protocols
principles in development of, 200
magnetic resonance imaging (MRI) system, 177–88. *See also specific components*
actively shielded gradient coil, 184
components list, 187–8
computer systems, 177–80, 178*f*, 187
data acquisition system, 178*f*, 186–8
diagram of, 178*f*
gradient system, 178*f*, 182–4, 188
magnet system, 178*f*, 180–2, 187
RF transmitter system, 178f, 184–6, 185*f*, 188
magnetic resonance (MR) signal, 12, 13*f*
magnetic resonance spectroscopy (MRS), 162–76
chemical shift in, 162–4, 163*f*, 164*f*
concepts, 162–7, 163*f*, 164*f*, 166*f*
hydrogen, 162–76
localization techniques, 167–9, 168*f*
multiple voxel techniques, 169, 170*f*
single voxel techniques, 167–9, 168*f*
spectral analysis and postprocessing steps, 169, 171–3, 171*f*, 172*f*, 174*f*, 175*f*
spectral linewidth in, 163*f*, 165–7, 166*f*
spin coupling in, 164–5, 166*f*
SVS in, 167–9, 168*f*

ultra-high field spectroscopy, 173, 175–6, 176*f*
water suppression in, 167
magnetic susceptibility, 8–9
magnetic susceptibility difference artifact, 117, 118*f*, 120–1, 121*f*
magnetization materials
susceptibility and, 8–9
magnetization-prepared (MP) pulses
incorporated into gradient echo and EPI sequences, 82–5, 83*f*–5*f*
magnetization-prepared (MP) sequences, 77–85, 78*f*, 78*t*, 79*f*, 81*f*–4*f*
example of, 78, 78*f*, 78*t*
magnetization transfer (MT) pulse, 96
in time-of-flight MRA, 138
magnetization transfer (MT) suppression, 96–9, 97*f*, 98*f*
MAST. *See* motion artifact suppression techniques (MAST)
maximum intensity projection (MIP)
MRA–related, 144–6, 145*f*, 146*f*
maximum signal content
site of, 48
measurement controller
in MRI system, 178, 178*f*
measurement hardware
as artifact, 122–4
measurement parameters, 86–93
extrinsic parameters, 89–91, 90*f*
effects of, 92*t*
intrinsic parameters, 87–9, 87*f*–9*f*
effects of, 92*t*
modification of, 86
parameter tradeoffs, 91–3, 92*t*
measurement protocol
criteria in determining, 91–2
measurement techniques
differentiating, 35–7
MIP. *See* maximum intensity projection (MIP)
modulation
in RV waveform characterization, 40
motion
Brownian, 147
intravoxel incoherent, 148–9
motion artifact(s), 103–5, 105*f*, 106*f*
appearance of, 104
causes of, 103–4
flow misregistration artifact, 104, 105*f*, 106*f*
respiratory, 104–5, 106*f*
types of, 104, 105*f*, 106*f*
motion artifact reduction techniques, 126–34
acquisition parameter modification, 126–7, 127*f*, 128*f*
flow compensation, 132–3, 133*f*
radial-based motion compensation, 134, 134*f*
triggering gating, 127–32, 130*f*, 131*f*
motion artifact suppression techniques (MAST)
in motion artifact reduction, 132–3, 133*f*
MP sequences. *See* magnetization-prepared (MP) sequences
MR. *See* magnetic resonance (MR)
MRA. *See* magnetic resonance angiography (MRA)
MRI. *See* magnetic resonance imaging (MRI)
MRS. *See* magnetic resonance spectroscopy (MRS)
MT. *See* magnetization transfer (MT)
multiecho spin echo sequences, 67, 68*f*
multiple voxel techniques
in MRS, 169, 170*f*
musculoskeletal system
MRI applications in, 206, 207*f*–9*f*

N
nature of synthesizer mixing
in RV waveform characterization, 40
neck
safety precautions related to, 204–5
negative agents
in MRI, 195
net magnetization
described, 6–7, 7*f*, 8*f*
production of, 1–9
NMR. *See* nuclear magnetic resonance (NMR)
noble gas imaging, 159–61, 160*f*
noise
as artifact, 123*f*–4*f*, 124–5
nonrectilinear sampling, 56
nonsaturation methods, 101–2, 101*f*, 102*f*
nonselective pulses
in RV waveform characterization, 41, 41*f*
nuclear magnetic moments, 3*f*, 4
nuclear magnetic resonance (NMR), 1
nuclear spin, 2–4, 3*f*, 3*t*, 5*f*
nucleus(i)
spin of, 2–4, 3*f*, 3*t*
null time for tissue, 80
Nyquist frequency, 14, 32

O
oral agents
in MRI, 195
out-of-phase gradient echo
clinical applications for, 219
oversampling, 91
effects of, 107, 107*f*

P
PACS (picture archiving and communications system) unit, 178–9
parallel acquisition methods, 60–4, 63*f*, 64*f*
requirements for, 62, 64*f*
types of, 62, 63*f*
partial Fournier imaging, 53, 53*f*
pelvis
MRI applications in, 215, 217, 217*f*, 218*f*
Perflubron (perfluorocytylbromide [PFOB]), 195
perfluorocytylbromide (PFOB), 195
perfusion, 153–5, 154*f*–6*f*
perfusion blood flow
in diffusion measurement, 148–9
perfusion studies
applications of, 154–5, 154*f*–6*f*
approaches to, 153
PFOB. *See* perfluorocytylbromide (PFOB)
PGSE. *See* pulsed gradient spin echo (PGSE) method

phase
  in RV waveform characterization, 40
phase cancellation artifact, 110–11, 111*f*, 111*t*
phase contrast MRA, 141–4, 143*f*–4*f*
phase encoding
  in MRI, 33–5, 33*f*, 34*f*
phased-array coils, 58–9, 60*f*, 61*f*
picture archiving and communications system (PACS) unit, 178–9
point resolved spectroscopy (PRESS), 167–9, 168*f*
postprocessing
  in MRS, 169, 171–3, 171*f*, 172*f*, 174*f*, 175*f*
pregnancy
  MRI during, 196
PRESS. *See* point resolved spectroscopy (PRESS)
projection reconstruction, 57, 58*f*
PROPELLER, 134, 134*f*
PSAL. *See* pulsed arterial spin labeling (PSAL)
pseudodiffusion, 149
pulse(s)
  composite, 44–5, 45*f*
  frequency selective, 41–4, 42*f*, 43*f*, 99–101, 99*f*, 100*f*
  frequency selective soft, 41–4, 42*f*, 43*f*
  Gaussian, 42, 43*f*
  gradient, 183
  hard, 41, 41*f*
  hyperbolic secant, 42, 43*f*
  MP
    incorporated into gradient echo and EPI sequences, 82–5, 83*f*–5*f*
  MT, 96–9, 97*f*, 98*f*
    in time-of-flight MRA, 138
  nonselective, 41, 41*f*
    in RV waveform characterization, 41, 41*f*
  RF excitation, 44
  in RV waveform characterization, 39–44, 41*f*–3*f*. *See also specific types*
  sinc, 41–2, 42*f*, 43*f*
  soft, 41–4, 42*f*, 43*f*
  spatial presaturation, 94–6, 95*f*
pulse sequence(s), 65–85. *See also specific types*
  comparison of, 65–7, 66*f*
  defined, 65
  EPI sequences, 75–7, 76*f*
  gradient echo sequences, 70–5, 71*t*, 72*f*–5*f*
  implementation of, 65
  IR pulse sequences, 78–80, 78*f*, 78*t*
  MP sequences, 77–85, 78*f*, 78*t*, 79*f*, 81*f*–4*f*
  spin echo sequences, 67–70, 67*t*, 68*f*, 69*f*
  timing diagrams in comparison of, 66–7, 66*f*
pulse shape
  in RV waveform characterization, 41, 41*f*
pulsed arterial spin labeling (PSAL), 153
pulsed gradient spin echo (PGSE) method, 148, 148*f*

R

radial artifact, 119, 120*f*
radial-based motion compensation
  in motion artifact reduction, 134, 134*f*
radial scanning, 57, 58*f*
radiofrequency (RF) excitation
  in MR, 10–12, 11*f*
  selective, 39–44, 41*f*–3*f*
radiofrequency (RF) excitation pulses
  criteria for, 44
radiofrequency (RF) power deposition
  safety precautions related to, 198–9
radiofrequency (RF) signal detection
  in MR, 12–14, 13*f*, 14*f*
radiofrequency (RF) transmitter system
  in MRI system, 178f, 184–6, 185*f*, 188
radiofrequency (RF) waveform
  parameters in characterizing, 39–44, 41*f*–3*f*
ramped sampling, 56–7, 57*f*
raw data, 46–7, 46*f*, 47*f*
  k-space and, 48–50, 49*f*, 51*f*
readout, 30–2, 31*f*, 32*f*
reduced *k*-space techniques, 51–3, 52*f*, 53*f*
refocused gradient echo sequences, 71*t*, 72–5, 72*f*–5*f*
  described, 72
  signals measured from, 73–5, 73*f*, 74*f*
relaxation, 17–25
  defined, 17
  spin–spin, 21–2, 21*f*
  T1
    saturation and, 17–21, 18*f*–20*f*
  T2, 21–5, 21*f*, 22*f*, 25*f*
  *T2**, 22*f*, 23–4, 25*f*
relaxation agents
  in MRI. *See specific agents and* contrast agents
reordered *k*-space filling techniques, 54–5, 54*f*–6*f*
repetition time *(TR)*, 87, 87*f*
respiratory motion artifact, 104–5, 106*f*
RF. *See* radiofrequency (RF)
rise time, 183

S

safety precautions, 196–9
  base magnetic field, 197
  contrast agents, 199
  cryogens, 197–8
  FDA on, 196
  gradients, 198
  IEC on, 196
  pregnancy-related, 196
  RF power deposition, 198–9
saturation
  T1 relaxation and, 17–21, 18*f*–20*f*
scanner controller
  in MRI system, 177–8, 178*f*
"schimming," 122
sedated patients
  MRI in, 221
"seed" region, 146
Send/Receive, 180
sequence looping, 35–8, 36*f*, 37*f*
sequence protocol–related artifacts, 105, 107–19
  aliasing, 105, 107–8, 107*f*–10*f*
  chemical shift artifacts, 108–10, 109*f*
  coherence artifacts, 113, 115–17, 115*f*–18*f*

magnetic susceptibility difference artifact, 117, 118*f*
phase cancellation artifact, 110–11, 111*f*, 111*t*
radial artifact, 119, 120*f*
truncation artifacts, 112, 112*f*–14*f*
shoulder
MRI applications in, 209*f*
signal suppression techniques, 94–102
Dixon method, 102, 102*f*
frequency selective saturation, 99–101, 99*f*, 100*f*
MT suppression, 96–9, 97*f*, 98*f*
nonsaturation methods, 101–2, 101*f*, 102*f*
spatial presaturation, 94–6, 95*f*
water excitation, 101, 101*f*
signal-to-noise ratio (SNR), 14
increase in, 91
in *k*-space–based techniques, 64
in parallel acquisition methods, 61–2
tradeoffs, 47–8
Simultaneous Acquisition of Spatial Harmonics (SMASH), 63–4
sinc pulses
in RV waveform characterization, 41–2, 42*f*, 43*f*
single-echo spin echo sequence, 67, 68*f*
clinical applications for, 218–19
single voxel spectroscopy (SVS)
in MRS, 167–9, 168*f*
single voxel techniques
in MRS, 167–9, 168*f*
slice gap, 89–90, 90*f*
slice selection
in MRI, 28–9, 28*f*–30*f*
slice thickness *(TH)*, 89
SMASH (Simultaneous Acquisition of Spatial Harmonics), 63–4
SNR. *See* signal-to-noise ratio (SNR)
soft pulses
in RV waveform characterization, 41–4, 42*f*, 43*f*
spatial presaturation, 94–6, 95*f*
spatial presaturation pulse, 94–6, 95*f*
spectral analysis
in MRS, 169, 171–3, 171*f*, 172*f*, 174*f*, 175*f*
spectral linewidth
in MRS, 163*f*, 165–7, 166*f*
spike(s)
defined, 123*f*, 125
spin coupling
in MRS, 164–5, 166*f*
spin echo(es), 21–5, 21*f*, 22*f*, 25*f*
spin echo sequences, 67–70, 67*t*, 68*f*, 69*f*. *See also specific types*
acronyms for, 67*t*
ETSE, 69–70, 69*f*
multiecho, 67, 68*f*
single-echo, 67, 68*f*
types of, 67–8, 67*t*
spin echo–based sequences, 82–3
spine
MRI applications in, 205–6, 205*f*, 206*f*
spin–spin relaxation, 21–2, 21*f*
SPIO. *See* superparamagnetic iron oxide (SPIO)
spoiled gradient echo
clinical applications for, 219
spoiled gradient echo sequences, 71–2, 71*t*
standard multiecho spin echo
clinical applications for, 220
steady-state gradient echo sequences, 71*t*, 72–5, 72*f*–5*f*. *See also* refocused gradient echo sequences
STEAM. *See* stimulated echo acquisition method (STEAM)
Stejskal–Tanner method, 148, 148*f*
stimulated echo acquisition method (STEAM), 167–8, 168*f*
STIR imaging
clinical applications for, 220
stroke
diffusion-weighted imaging in evaluation of, 151–3
subloop(s)
in sequence looping, 35–6
superparamagnetic iron oxide (SPIO) particulate molecules, 194–5, 194*f*
surface coils, 59, 60*f*
susceptibility
bulk magnetic, 8–9
magnetic, 8–9
magnetization materials and, 8–9
SVS. *See* single voxel spectroscopy (SVS)

T

TCP/IP (Transmission Control Protocol/Internet Protocol)
in MRI system, 179
TE. See echo time *(TE)*
TH. See slice thickness *(TH)*
thorax
MRI applications in, 206–9
TI. See inversion time *(TI)*
time-of-flight MRA, 137–40, 137*f*–42*f*
time-resolved angiography with interleaved stochastic trajectories (TWIST), 138
time-resolved imaging of contrast kinetics (TRICKS), 138
timing diagram
in pulse sequence comparison, 66–7, 66*f*
T1 relaxation
defined, 17
saturation and, 17–21, 18*f*–20*f*
T1 relaxation agents
in MRI, 190–3, 191*f*, 192*t*–3*t*
T1-weighted imaging studies
in perfusion studies, 153
T1-weighted techniques
clinical applications for, 218–20. *See also specific techniques*
fat saturation
clinical applications for, 219–20
TR. See repetition time *(TR)*
Transmission Control Protocol/Internet Protocol (TCP/IP)
in MRI system, 179
TRICKS (time-resolved imaging of contrast kinetics), 138

triggering gating
in motion artifact reduction, 127–32, 130*f*, 131*f*
truncation artifacts, 112, 112*f*–14*f*
T2 effects
in diffusion measurement, 149, 150*f*
T2 relaxation, 21–5, 21*f*, 22*f*, 25*f*
*T2** relaxation, 22*f*, 23–4, 25*f*
defined, 23
T2 relaxation agents
in MRI, 194–5, 194*f*
T2-weighted imaging studies
in perfusion studies, 153
T2-weighted techniques
clinical applications for, 220–1
fat saturation
clinical applications for, 221
turbo factor, 88
TWIST (time-resolved angiography with interleaved stochastic trajectories), 138
two-dimensional spiral sampling, 58, 59*f*

U
ultra-high field imaging, 158–9
ultra-high field spectroscopy
in MRS, 173, 175–6, 176*f*

W
water excitation
for signal suppression, 101, 101*f*
water suppression
in MRS, 167

Z
Zeeman interaction, 6–7, 7*f*
zero filling, 171, 171*f*